Plasma cell marker, immunoglobulin J polypeptide, predicts early disease-specific mortality in HPV+ HNSCC.

Shanying GuiW Quinn O'NeillTheodoros N TeknosQuintin Pan

Published in: Journal for immunotherapy of cancer (2021)

Our work showed that IGJ is a robust and independent prognostic biomarker for disease-specific mortality in HPV+ HNSCC. Patient with HPV+ HNSCC with limited adaptive immune functionality should not be candidates for treatment de-escalation modalities.

Keyphrases

high grade
cardiovascular events
risk factors
cervical cancer screening
single cell
randomized controlled trial
cell therapy
type diabetes
clinical trial
stem cells
open label
cardiovascular disease
coronary artery disease
bone marrow
mesenchymal stem cells
combination therapy
double blind